Clinical course of ulcerative colitis

Digestive and Liver Disease

Volumn 40, Issue SUPPL. 2, 2008, Pages

  Cottone, M ^a   Scimeca, D ^a   Mocciaro, F ^a   Civitavecchia, G ^a   Perricone, G ^a   Orlando, A ^a  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

Author keywords

Cancer; Clinical course; Mortality; Ulcerative colitis

Indexed keywords

CYCLOSPORIN; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1; MESALAZINE; MULTIDRUG RESISTANCE PROTEIN; STEROID;

ARTICLE; CANCER RISK; CIGARETTE SMOKING; CLINICAL FEATURE; COHORT ANALYSIS; COLITIS; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EDUCATIONAL STATUS; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; INCIDENCE; LYMPHOMA; MORTALITY; POPULATION RESEARCH; PREDICTION; PROCTITIS; PROGNOSIS; QUALITY OF LIFE; RELAPSE; REMISSION; RISK ASSESSMENT; SMOKING CESSATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

CASE-CONTROL STUDIES; COLECTOMY; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STEROIDS;

EID: 45849113207     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(08)60533-2     Document Type: Article

References (44)

1. Sackett D., Haynes R., Guyatt G., and Tugwell P. Clinical epidemiology. A basic science for clinical medicine. 2nd ed. (1991), Little, Brown and Company, London
2. Langholz E., Munkholm P., Davidsen M., and Binder V. Course of ul-cerative colitis: analysis of changes in disease activity over years. Gastroenterology 107 (1994) 3-11
3. Langholz E., Munkholm P., Davidsen M., Nielsen O., and Binder V. Changes in extent of ulcerative colitis - a study on the course and prognostic factors. Scand J Gastroenterol 31 (1996) 260-266
4. Langholz E., Munkholm P., Nielsen O., Kreiner S., and Binder V. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 26 (1991) 1247-1256
5. Moum B., Vatn M., Ekbom A., Aadland E., Fausa O., Lygren I., et al. Incidence of ulcerative colitis and indeterminate colitis in four counties of southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists. Scand J Gastroenterol 31 (1996) 362-366
6. Broström O., Monsén U., Nordenwall B., Sörstad J., and Hellers G. Prognosis and mortality of ulcerative colitis in Stockholm county, 1955- 79. Scand J Gastroenterol 22 (1987) 907-913
7. Ekbom A., Helmick C., Zack M., Holmberg L., and Adami H. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology 103 (1992) 954-960
8. Loftus E., Silverstein M., Sandborn W., Tremaine W., Harm-sen W., and Zinsmeister A. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 46 (2000) 336-343
9. Palli D., Trallori G., Saieva C., Tarantino O., Edili E., D'Albasio G., et al. General and cancer specific mortality of a population-based cohort of patients with inflammatory bowel disease: the Florence study. Gut 42 (1998) 175-179
10. Lennard-Jones J., and Shivananda S. Clinical uniformity of inflammatory bowel disease at presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol 9 (1997) 353-359
11. Henriksen M., Jahnsen J., Lygren I., Sauar J., Kjellevold O., Schulz T., et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 12 (2006) 543-550
12. Hoie O., Wolters F., Riis L., Aamodt G., Solberg C., Bernklev T., et al. Ulcerative Colitis: Patient Characteristics May Predict 10-Yr Disease Recurrence in a European-Wide Population-Based Cohort. Am J Gastroenterol 102 (2007) 1-10
13. Sandborn W. Severe ulcerative colitis. Curr Treat Options Gas-troenterol 2 (1999) 113-118
14. Travis S., Farrant J., Ricketts C., Nolan D., Mortensen N., Kettlewell M., et al. Predicting outcome in severe ulcerative colitis. Gut 48 (2001) 526-535
15. Ho G., Mowat C., Goddard C., Fennell J., Shah N., Prescott R., et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 19 (2004) 1079-1087
16. Lichtiger S., Present D., Kornbluth A., Gelernt I., Bauer J., Galler G., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330 (1994) 1841-1845
17. Jarnerot G., Hertervig E., Friis-Liby I., Blomquist L., Karlen P., Granno C., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005) 1805-1811
18. Faubion W., Loftus E., Harmsen W., Zinsmeister A., and Sand-born W. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121 (2001) 255-260
19. George J., Present D., Pou R., Bodian C., and Rubin P. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 91 (1996) 1711-1714
20. Cummings J., and Jewell D. Clinical implications of inflammatory bowel disease genetics on phenotype. Inflamm Bowel Dis 11 (2005) 56-61
21. Calkins B. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci (1989) 1841-1854
22. Meucci G., Vecchi M., Astegiano M., Beretta L., Cesari P., Dizioli P., et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Am J Gastroenterol 95 (2000) 469-473
23. Boyko E., Perera D., Koepsell T., Keane E., and Inui T. Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol 23 (1988) 1147-1152
24. de Saussure P., Clerson P., Prost P., Truong Tan N., Bouhnik Y., and Gil-Rch. Appendectomy, smoking habits and the risk of developing ulcerative colitis: a case-control study in private practice setting. Gastroenterol Clin Biol 31 (2007) 493-497
25. Koutroubakis I., and Vlachonikolis I. Appendectomy and development of ulcerative colitis: results of a meta-analysis of published case-control studies. Am J Gastroenterol 95 (2000) 171-176
26. Radford-Smith G., Edwards J., Purdie D., Pandeya N., Watson M., Martin N., et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut 51 (2002) 808-813
27. Cosnes J., Carbonnel F., Beaugerie L., Blain A., Reijasse D., and Gendre J. Effects of appendectomy on the course of ulcerative colitis. Gut 51 (2002) 803-807
28. Eaden J., Abrams K., and Mayberry J. The risk ok colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48 (2001) 526-535
29. Langholz E., Munkholm P., Davidsen M., and Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterol-ogy 103 (1992) 1444-1451
30. Jess T., Loftus E., Velayos F., Harmsen W., Zinsmeister A., Smyrk T., et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. Gastroenterology 130 (2006) 1039-1046
31. Velayos F., Loftus E., Jess T., Harmsen W., Bida J., Zinsmeister A., et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology 130 (2006) 1941-1949
32. Thomas T., Abrams K., Robinson R., and Mayberry J. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 25 (2007) 657-668
33. Jess T., Loftus Jr. E., Velayos F., Winther K., Tremaine W., Zins-meister A., et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroen-terol 102 (2007) 829-836
34. Kwon J., and Farrell R. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol 56 (2005) 169-178
35. Connell W., Kamm M., Dickson M., Balkwill A., Ritchie J., and Lennard-Jones J. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343 (1994) 1249-1252
36. Kandiel A., Fraser A., Korelitz B., Brensinger C., and Lewis J. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 (2005) 1121-1125
37. Palli D., Trallori G., Bagnoli S., Saieva C., Tarantino O., Ceroti M., et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 119 (2000) 647-653
38. Probert C., Jayanthi V., Wicks A., and Mayberry J. Mortality in patients with ulcerative colitis in Leicestershire, 1972-1989. An epidemiological study. Dig Dis Sci 38 (1993) 538-541
39. Persson P., Bernell O., Leijonmarck C., Farahmand B., Hellers G., and Ahlbom A. Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 110 (1996) 1339-1345
40. Farrokhyar F., Swarbrick E., Grace R., Hellier M., Gent A., and Irvine E. Low mortality in ulcerative colitis and Crohn's disease in three regional centers in England. Am J Gastroenterol 96 (2001) 501-507
41. Masala G., Bagnoli S., Ceroti M., Saieva C., Trallori G., Zanna I., et al. Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn's disease patients: the Florence IBD study 1978-2001. Gut 53 (2004) 1309-1313
42. Höie O., Schouten L., Wolters F., Solberg I., Riis L., Mouzas I., et al. Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis. Gut 56 (2007) 497-503
43. Jess T., Gamborg M., Munkholm P., and Sørensen T. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol 102 (2007) 609-617
44. Sonnenberg A. Time trends of mortality from Crohn's disease and ulcerative colitis. Int J Epidemiol 36 (2007) 890-899